bardoxolone Articles
FDA extends PDUFA date for Biogen Idec's MS drug BG-12; Abbott and Reata's bardoxolone stalled
19 October 2012
Abbott in further deal with Reata
12 December 2011
Abbott enters $450 million deal with Reata Pharma to gain rights to methyl for kidney disease outside USA
24 September 2010
Showing 1-3 of 3 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
